.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Chinese Patent Office
Colorcon
Argus Health
Novartis
Fish and Richardson
Cantor Fitzgerald
Cerilliant
McKinsey
Medtronic

Generated: September 24, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-an- ilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulpho- nate and the use thereof as a pharmaceutical composition
Abstract: The present invention relates to the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycabonyl-2-indolinone-monoethanesulpho- nate of formula I and the use thereof as a pharmaceutical composition ##STR00001##
Inventor(s): Roth; Gerald J. (Biberach, DE), Linz; Guenter (Mittelbiberach, DE), Sieger; Peter (Mittelbiberach, DE), Rall; Werner (Mittelbiberach, DE), Hilberg; Frank (Wien, AT), Bock; Thomas (Biberach, DE)
Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim, DE)
Application Number:10/623,971
Patent Claims: 1. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino- )-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesu- lphonate.

2. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino- )-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesu- lphonate hemihydrate in crystalline form, having a melting point of T.sub.m.p.=305.+-.5.degree. C. (determined by DSC; evaluation using peak-maximum; heating rate: 10.degree. C./min).

3. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate hemihydrate according to claim 2, the X-ray powder diagram of which includes, inter alia, the characteristic values d=5.43 .ANG., 5.08 .ANG., 4.71 .ANG., 4.50 .ANG. and 4.43 .ANG. with an intensity of more than 40%.

4. Crystalline 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate hemihydrate according to claim 2, characterised by a unit cell determined by X-ray powder diffractometric measurements having the following dimensions: a=16.332 .ANG., b=19.199 .ANG., c=11.503 .ANG., .alpha.=95.27.degree., .beta.=90.13.degree., .gamma.=110.83.degree. and V=3354.4 .ANG..sup.3.

5. A pharmaceutical composition comprising 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate and one or more inert carriers and/or diluents.

6. A prodrug of 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-a- nilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulph- onate.

7. 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino- )-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesu- lphonate hemihydrate in crystalline form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Fuji
McKinsey
Fish and Richardson
Baxter
Moodys
AstraZeneca
Express Scripts
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot